Business
Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab
Combination cohort initiated following successful review of monotherapy cohortOver 100 participants dosed to-date in monotherapy cohortPriority are Head and Neck Squamous Cell Carcinoma (HNSCC) and cervical cancerData update on schedule for later this year NORWOOD, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on oncology and obesity, today announced the dosing of the first participant i
About this update from Corbus Pharmaceuticals Holdings, Inc.
[{"type":"image","alt":"Corbus Pharmaceuticals Holdings, Inc.","displaySize":"","headline":null,"caption":"Corbus Pharmaceuticals Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":169,"url":"https://media.zenfs.com/en/globenewswire.com/b0d3415d4cf3d45a0ffce87aeff8ec18"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/z7Iu.c3o3K9KWXFezgFH1w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b0d3415d4cf3d45a0ffce87aeff8ec18","width":300,"height":169}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Combination cohort initiated following successful review of monotherapy cohort","length":78,"tagName":"p"}]},{"val":[{"type":"text","content":"Over 100 participants dosed to-date in monotherapy cohort","length":57,"tagName":"p"}]},{"val":[{"type":"text","content":"Priority are Head and Neck Squamous Cell Carcinoma (HNSCC) and cervical cancer","length":78,"tagName":"p"}]},{"val":[{"type":"text","content":"Data update on schedule for later this year","length":43,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":256,"olType":false},{"type":"text","content":"NORWOOD, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on oncology and obesity, today announced the dosing of the first participant in the PD-1 combination arm of its Phase 1 study investigating CRB-701 in solid tumors (the Phase 1 Western study). Participants in this arm of the study are being randomized to the 2.7 mg/kg and 3.6 mg/kg cohorts in combination with Keytruda® (pembrolizumab).","length":502,"tagName":"p"},{"type":"text","content":"“We are very pleased to reach this important milestone and with such an encouraging rate of enrollment in our CRB-701 program,” said Dr. Dominic Smethurst, MA MRCP, Chief Medical Officer of Corbus. “CRB-701 data demonstrates differentiated safety, tolerability and efficacy profiles in HNSCC, cervical and mUC tumors.”","length":318,"tagName":"p"},{"type":"text","content":"The three-part Phase 1 study (NCT06265727) is evaluating the safety, pharmacokinetics and efficacy of CRB-701 in participants with advanced solid tumors associated with high Nectin-4 expression. The Part A dose escalation of the study evaluated four predetermined dos...